Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA To Draw Up 'Critical Medicine' Lists For Future Health Crises

Industry Will Be ‘Invited’ To Review Product Lists

Executive Summary

As part of its expanded mandate, the EU regulator is identifying those medicines whose supply will need to be closely monitored during health crisis situations. The lists will draw on various information sources, including real-world evidence databases.

You may also be interested in...

French Industry Chief On How To Encourage Innovation & Avoid Drug Shortages

Pricing challenges, high taxes and the growing problem of drug shortages have led the pharmaceutical industry body Leem to come forward with a set of proposals that it says should inform future government policy towards the sector.

EU Health Crisis Package Includes Supply Chain Revamps, Central Procurement & Regulatory Flexibility

The European Commission says that all the legislation for the creation of the European Health Union is now in place, following the publication of regulations on the supply and availability of medical countermeasures, centrally coordinated procurement mechanisms, and “ever-ready” manufacturing capacity for use in health emergencies.

EMA Publishes List Of ‘Critical’ COVID-19 Products

A steering group set up by the EU regulator has produced a list of five vaccines and nine therapeutics that it deems essential for use in preventing and treating COVID-19. It will also draw up a list of critical medicines for use in emergency and intensive care during health crises.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts